SG11201906422VA - Apoc-ii mimetic peptides - Google Patents

Apoc-ii mimetic peptides

Info

Publication number
SG11201906422VA
SG11201906422VA SG11201906422VA SG11201906422VA SG11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA
Authority
SG
Singapore
Prior art keywords
international
delta
gatehouse
rockville
suite
Prior art date
Application number
SG11201906422VA
Other languages
English (en)
Inventor
Alan Remaley
Soumitra Ghosh
Madhav Devalaraja
Chih-Hung Lo
Denis Sviridov
Anna Wolska
Original Assignee
Us Health
Corvidia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Corvidia Therapeutics Inc filed Critical Us Health
Publication of SG11201906422VA publication Critical patent/SG11201906422VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201906422VA 2017-01-19 2018-01-19 Apoc-ii mimetic peptides SG11201906422VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (1)

Publication Number Publication Date
SG11201906422VA true SG11201906422VA (en) 2019-08-27

Family

ID=62908746

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906422VA SG11201906422VA (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides
SG10201911974UA SG10201911974UA (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201911974UA SG10201911974UA (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Country Status (14)

Country Link
US (2) US11136372B2 (enExample)
EP (1) EP3571216A4 (enExample)
JP (2) JP7353973B2 (enExample)
KR (1) KR102700862B1 (enExample)
CN (1) CN110831957B (enExample)
AU (1) AU2018210404B2 (enExample)
BR (1) BR112019014707A2 (enExample)
CA (1) CA3050106A1 (enExample)
IL (2) IL268093B2 (enExample)
MX (1) MX2019008529A (enExample)
NZ (1) NZ755599A (enExample)
SG (2) SG11201906422VA (enExample)
TW (2) TWI788323B (enExample)
WO (1) WO2018136803A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117580857A (zh) * 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) Apoc-ii短模拟肽及使用方法
WO2023215838A1 (en) * 2022-05-05 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Short apolipoprotein e mimetic peptides and methods of use
EP4565251A1 (en) * 2022-08-07 2025-06-11 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US7691860B2 (en) * 2004-02-19 2010-04-06 Banyu Pharmaceutical Co., Ltd. Sulfonamide derivatives
US7569546B2 (en) * 2004-07-16 2009-08-04 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
EP2484692A4 (en) 2009-09-30 2013-03-06 Snu R&Db Foundation MIMETIC APOLIPOPROTEIN A-1-PEPTIDES AND THERAPEUTICS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA THEREWITH
BR112015010276A2 (pt) 2012-11-06 2019-10-15 Hoffmann La Roche peptídeos miméticos
WO2018136803A1 (en) 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary Departmetn Of Health & Human Services Apoc-ii mimetic peptides
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides

Also Published As

Publication number Publication date
MX2019008529A (es) 2020-02-07
AU2018210404A1 (en) 2019-08-08
SG10201911974UA (en) 2020-02-27
US20200140522A1 (en) 2020-05-07
NZ755599A (en) 2022-12-23
WO2018136803A1 (en) 2018-07-26
IL279831A (en) 2021-03-01
JP7353973B2 (ja) 2023-10-02
AU2018210404B2 (en) 2022-01-27
TW202130652A (zh) 2021-08-16
IL268093B1 (en) 2024-03-01
TWI788323B (zh) 2023-01-01
IL268093A (en) 2019-09-26
TW201835097A (zh) 2018-10-01
IL268093B2 (en) 2024-07-01
EP3571216A1 (en) 2019-11-27
BR112019014707A2 (pt) 2020-04-07
EP3571216A4 (en) 2020-11-04
KR102700862B1 (ko) 2024-08-30
US11827690B2 (en) 2023-11-28
CA3050106A1 (en) 2018-07-26
US20210324043A1 (en) 2021-10-21
JP2020511425A (ja) 2020-04-16
WO2018136803A8 (en) 2019-08-01
US11136372B2 (en) 2021-10-05
JP2023116739A (ja) 2023-08-22
CN110831957B (zh) 2024-02-09
KR20190121305A (ko) 2019-10-25
CN110831957A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
SG11201908391XA (en) Methods for modulating an immune response
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201809381XA (en) Polynucleotides encoding interleukin-12 (il12) and uses thereof
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof